Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oxycodone

- PMLiVE

FDA approves pain drug that has reduced risk of abuse

Purdue’s Targiniq ER developed to deter snorting and injection

- PMLiVE

Interview: Georg Toufar, Mundipharma

Mundipharma’s chief marketing officer Georg Toufar on the benefits of having a smaller, more concentrated focus

- PMLiVE

Pain management teaching shortfall

MundiPharma-backed study that find medical students in Europe are receiving insufficient training in pain

- PMLiVE

Saatchi & Saatchi create Spanish restless legs syndrome campaign

Online public awareness push is in collaboration with UCB

- PMLiVE

VCCP Health wins Mundipharma’s new product launch business

Agency hired to drive new product launches across Europe

- PMLiVE

US shortage of GSK’s restless legs syndrome treatment Horizant

FDA blames contract manufacturer delays

Portland Health wins Mundipharma account

Handling communications for the pain, oncology and asthma specialist

- PMLiVE

GSK and XenoPort end restless legs syndrome collaboration

Follows tough approval period for Horizant and subsequent poor sales 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links